Chromosome 17p13 deletion is associated with an aggressive tumor phenotype in clear cell renal cell carcinoma

Autor: Ronald Simon, Christina Möller-Koop, Till S. Clauditz, Claudia Hube-Magg, Franziska Büscheck, Christoph Fraune, Sarah Minner, Guido Sauter, Roland Dahlem, Till Eichenauer, Silke Riechardt, Eike Burandt, Navid Shadanpour, Martina Kluth, Christian Bernreuther, Waldemar Wilczak, Sören Weidemann, Margit Fisch, Cosima Göbel, Michael Rink
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
lcsh:Surgery
Chromosomal translocation
Chromophobe cell
urologic and male genital diseases
lcsh:RC254-282
Tissue microarray
03 medical and health sciences
0302 clinical medicine
Renal cell carcinoma
Surgical oncology
medicine
Humans
Carcinoma
Renal Cell
In Situ Hybridization
Fluorescence
Renal cell cancer
medicine.diagnostic_test
business.industry
Research
Fluorescence in situ hybridization
lcsh:RD1-811
medicine.disease
Prognosis
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Kidney Neoplasms
female genital diseases and pregnancy complications
Survival Rate
Clear cell renal cell carcinoma
Phenotype
030104 developmental biology
Oncology
Tissue Array Analysis
030220 oncology & carcinogenesis
Cancer research
Surgery
Chromosome Deletion
business
Clear cell
17p13 deletion
Chromosomes
Human
Pair 17
Zdroj: World Journal of Surgical Oncology, Vol 18, Iss 1, Pp 1-9 (2020)
World Journal of Surgical Oncology
ISSN: 1477-7819
DOI: 10.1186/s12957-020-01902-y
Popis: Background Deletions of 17p13 recurrently occur in renal cell carcinoma (RCC) but their prognostic role seems to be uncertain. Methods To determine prevalence, relationship with tumor phenotype, and patient prognosis, a tissue microarray containing samples from 1809 RCCs was evaluated using dual labeling fluorescence in situ hybridization (FISH) with 17p13 and chromosome 17 centromere probes. Results A 17p13 deletion was found in 72 of 1429 interpretable tumors. The frequency of 17p13 deletions varied greatly between RCC subtypes and was highest in chromophobe RCC (24/72; 33.3%). 17p13 deletions were also found in 35 (3.7%) of 946 clear cell RCC, 9 (4.3%) of 208 papillary RCC, 1 of 121 oncocytomas (0.8%), as well as in several rare cases of comprising 1 of 7 Xp11.2 translocation cancers, 1 of 3 collecting duct carcinomas, and 1 of 20 not otherwise specified (NOS) carcinomas. In clear cell carcinomas, 17p13 deletions revealed a strong and consistent association with higher Fuhrman, ISUP, and Thoenes grade (p < 0.0001 each), and linked to advanced tumor stage (p = 0.0168), large tumor diameter (p = 0.0004), distant metastases (p = 0.0077), cancer-specific survival (p = 0.0391), and recurrence-free survival (p = 0.0072). In multivariate analysis, 17p13 deletions showed in clear cell RCC a dependent prognostic role for established clinical-pathological parameters. Conclusion 17p13 deletions have a dual role in RCC. They are associated with disease progression in clear cell RCC and possibly other subtypes and they are linked to the development of chromophobe RCC—a subtype with a particularly favorable prognosis.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje